Key result
Caffeic acid improves LVEF and attenuates post-infarct myocardial fibrosis by inhibiting p38 MAPK signaling.
Why the study?
Does caffeic acid attenuate myocardial fibrosis and improve cardiac function by suppressing MAPKs/CREB-mediated inflammation in a murine model of myocardial ischemia–reperfusion injury?
Does caffeic acid attenuate myocardial fibrosis and improve cardiac function by suppressing MAPKs/CREB-mediated inflammation in a murine model of myocardial ischemia–reperfusion injury?
This preclinical study demonstrates that caffeic acid mitigates post-ischemia–reperfusion myocardial fibrosis and dysfunction by inhibiting macrophage-driven MAPKs/CREB inflammatory signaling, identifying it as a potential therapeutic candidate for preventing adverse cardiac remodeling.
Should not change MIRI management; hypothesis-generating for caffeic acid via p38 MAPK suppression in reperfusion injury.
Background Myocardial ischemia–reperfusion injury (MIRI) represents a major form of secondary damage during reperfusion therapy, in which inflammation and myocardial fibrosis are key pathological features. Caffeic acid (CA), a natural phenolic compound abundant in dietary sources, has been implicated in cardiovascular protection; however, the mechanisms by which CA modulates post-MIRI inflammation and fibrosis remain insufficiently defined. Objective To clarify the molecular target(s) and signaling mechanism(s) through which CA attenuates inflammation-associated myocardial fibrosis after MIRI. Methods A LAD ligation–based murine MIRI model was used to evaluate the anti-inflammatory and anti-fibrotic efficacy of CA. A co-culture system using cardiac fibroblasts and RAW 264.7 macrophages, along with adoptive cell transfer, was applied to interrogate macrophage–fibroblast crosstalk. Transcriptomic profiling (RNA-seq) was performed to identify candidate pathways involved in CA-mediated protection. Surface plasmon resonance (SPR) assay, CETSA, immunofluorescence, and western blotting were used to assess MAPKs/CREB signaling as a putative intervention axis, and pharmacological activation of MAPKs (anisomycin) or CREB (forskolin), or MAPK14 ablation, was employed to probe pathway involvement. Results CA improved cardiac function and alleviated inflammatory and fibrotic pathology in MIRI mice, accompanied by suppression of pro-inflammatory cytokines. Conditioned medium from LPS-stimulated RAW 264.7 cells promoted fibroblast activation, and adoptively transferred macrophages within the myocardium promoted fibrotic protein expression; both effects were attenuated by CA. RNA-seq implicated MAPK signaling in the protective mechanism of CA, and downstream analyses supported inhibition of the MAPKs/CREB axis. Notably, CA achieved effects comparable to those of MAPK14 ablation, whereas anisomycin or forskolin partially blunted the anti-inflammatory and anti-fibrotic effects of CA, consistent with functional involvement of MAPKs/CREB signaling in CA-mediated protection during MIRI. Conclusion CA mitigates MIRI-associated myocardial fibrosis by suppressing MAPKs/CREB-mediated inflammatory signaling, supporting its potential to improve long-term post-MIRI remodeling.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2026) studied Myocardial ischemia-reperfusion injury (MIRI) and myocardial fibrosis. Caffeic acid (CA) vs. Normal saline (vehicle) or pirfenidone (300 mg/kg/day) was evaluated on Cardiac function (LVEF and LVFS) and myocardial fibrosis at day 14 post-MIRI. Caffeic acid (50 mg/kg/day) significantly improved LVEF and LVFS and attenuated myocardial fibrosis in MIRI mice by binding p38 MAPK (KD = 7.37 μM) and suppressing MAPKs/CREB signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: